Brady T, Gore J, Wells JW, moderators, Magnetic Resonance in Medicine, 1991; 22:229-32.
Carr JJ. Magnetic resonance contrast agents for neuroimaging: safety issues, Neuroimaging Clinics of North America, 1994; 4(1):43-54.
Chang CA. Magnetic resonance imaging contrast agents: design and physiochemical properties of gadodiamide, Investigative Radiology, 1993; 28:S21-27.
Dawson P. Contrast agents in magnetic resonance imaging, European Journal of Radiology, 1996; 23:201-4.
Dawson P, Cosgrove DO, Grainger RG, eds. Textbook of contrast media. Oxford, UK: Isis Medical Media Ltd; 1999.
Earls JP, Bluemke DA. New MR imaging contrast agents, MRI Clinics of North America, May 1999; 7(2):255-73.
Gibby WA. MR contrast agents: an overview, Radiology Clinics of North America, September 1988; 26:1047-58.
Magnevist (gadopentetate dimeglumine) injection package insert. Germany: Berlex Laboratories; March 2000.
Nelson KL, Runge VM. Basic principles of MR contrast, Topics in Magnetic Resonance Imaging, 1995; 7(3):124-36.
Niendorf HP, Haustein J, Cornelius I et al. Safety of gadolinium-DTPA: extended clinical experience, Magnetic Resonance in Medicine, 1991; 22:222-8.
Nitz WR, Reimer P. Contrast mechanisms in MR imaging, European Radiology, 1999; 9:1032-46.
Omniscan (gadodiamide) injection package insert. Oslo, Norway: Amersham Health; November 2001.
Runge VM, Wells JW. Update: safety, new applications, new MR agents, Topics in Magnetic Resonance Imaging, 1995; 7(3):181-95.
Swanson DP, Chilton DM, Thrall JH. Pharmaceuticals in medical imaging: radiopaque contrast media, radiopharmaceuticals, enhancement agents for magnetic resonance imaging and ultrasound. New York: Macmillan; 1990.
Yuh WTC, Parker JR, Carvlin MJ. Indication-related dosing for magnetic resonance contrast media, European Radiology, 1997; 7 (Suppl. 5):S269-75.
Copyright © 2002 AuntMinnie.com